Compare Nomura Holdings Inc (NMR) vs Repligen Corporation Common Stock (RGEN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nomura Holdings Inc vs Repligen Corporation Common Stock — how do they compare? Nomura Holdings Inc trades at $9.2 (market cap $28.01B), while Repligen Corporation Common Stock trades at $178.86 (market cap $11.14B). The key difference: Nomura Holdings Inc is far larger — about 2.5× Repligen Corporation Common Stock's market cap, and Nomura Holdings Inc pays a 3.38% dividend while Repligen Corporation Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Nomura Holdings Inc for 56 Days and Repligen Corporation Common Stock for 0 Days on average.
| NMR | RGEN | |
|---|---|---|
Market Cap | $28.01B | $11.14B |
Volume | 686,801 | 1,259,263 |
Sector | Financials | Health |
52-Week High | $10.86 | $194.57 |
52-Week Low | $6.92 | $102.87 |
Typical Hold Time | 56 Days | 0 Days |
Enterprise Value | $38.48T | $11.02B |
Dividend Yield | 3.38% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Nomura Holdings (NMR) trades at $9.26, down 3.24% with bearish technical signals. The stock shows mixed earnings performance with recent misses but strong revenue growth from $1.66T in 2025. Valuation appears attractive with P/E of 11.37 and P/B of 1.16, while analyst sentiment leans cautious with 67% hold ratings. Recent Zacks coverage highlights momentum potential and hammer chart pattern formation.
Outlook remains balanced with fundamental strength in profitability margins (20.4% net income) offset by technical weakness. Investment opportunity lies in discounted valuation amid earnings growth, while risks include cash flow volatility and rising debt levels. The stock requires careful monitoring of Q3 2026 earnings results for directional clarity.
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Nomura Holdings Inc
Nomura is Japan's largest broker, about twice the size of rival Daiwa Securities and roughly three times the size of the securities units of the three megabanks. It is also the largest asset-management company in Japan, with a similar size differential compared with its rivals. Despite its topnotch brand name in retail broking and asset management in Japan, Nomura has struggled to compete effectively in the institutional securities business against larger global rivals. In 2008, Nomura bought European and Asian assets of the failed Lehman Brothers, which led to a sharply higher cost base but did not provide commensurate revenue. Nomura has reduced the scale of these businesses but maintains its ambition to compete globally with the top players.
Read more on NMR →About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →
